
    
      This Phase 2/3 trial will enroll a total of 7320 male and female subjects randomized in a
      double-blind manner to receive either UB-612 or placebo. Assignment will be stratified by age
      (18 to 59 years and â‰¥60 years) and by presence/absence of comorbidities.

      All subjects will receive 2 doses of the study vaccine, separated by 28 days, as an
      intramuscular (IM) injection.

      Phase 2 and Phase 3 will start simultaneously; Phase 2 will enroll all Strata #1 to #4; Phase
      3 will enroll Stratum #1 until the Data and Safety Monitoring Board (DSMB) has reviewed Phase
      2 data through Day 43 and endorsed enrolment of Strata #2 to #4. All subjects in Phase 2 and
      Phase 3 will be followed for safety and efficacy.

      This Phase 2/3 study also contains a Safety and Immunogenicity Cohort (N=1300) consisting of
      1000 SARS-CoV-2 seronegative subjects (320 subjects enrolled in Phase 2 and 680 subjects
      enrolled in Phase 3) and 300 SARS-CoV-2 seropositive subjects enrolled in Phase 3.
    
  